Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

Chidambaram,Ranganathan; Terunuma,Hiroshi; Balamurugan,Madasamy; Dedeepiya,Vidyasagar   Devaprasad; Sumana,Premkumar; Senthilkumar,Rajappa; Rajmohan,Mathaiyan; Karthick,Ramalingam; Preethy,Senthilkumar; Abraham,Samuel   J.K.

doi:10.3892/mco.2017.1333

Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

Authors:
- Ranganathan Chidambaram
- Hiroshi Terunuma
- Madasamy Balamurugan
- Vidyasagar Devaprasad Dedeepiya
- Premkumar Sumana
- Rajappa Senthilkumar
- Mathaiyan Rajmohan
- Ramalingam Karthick
- Senthilkumar Preethy
- Samuel J.K. Abraham
View Affiliations

Affiliations: RUMA Biotherapy and Research Centre, Moolakulam, Puducherry‑605010, India, Biotherapy Institute of Japan, Tokyo 135‑0051, Japan, The Mary‑Yoshio Translational Hexagon (MYTH), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai, Tamil Nadu 600034, India, Chennai Meenakshi Multispeciality Hospital Limited, Chennai, Tamil Nadu 600004, India, The Fujio‑Eiji Academic Terrain (FEAT), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai, Tamil Nadu 600034, India, Department of Surgery, Υamanashi University School of Medicine, Chuo, Yamanashi 409‑3898, Japan
Published online on: July 19, 2017 https://doi.org/10.3892/mco.2017.1333
Pages: 493-497

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells in breast cancer migrating to the bone marrow may cause future metastasis, particularly during periods of decreased immunity. Natural killer (NK) cells have a role in immune surveillance and are able to target cancer stem cells. The present study reported a case in which NK cell‑based autologous immune enhancement therapy was used combined with conventional treatments in a patient with stage IIIA breast cancer, yielding >28 months of disease‑free survival. However, there was a gradual decline in the in vitro expansion of NK cells with subsequent chemotherapeutic treatments. As this NK cell decline following chemotherapy may contribute to cancer cell immune evasion and future metastasis; modifying current cancer therapies in order to avoid potentially compromising the immune system may lead to improved treatment outcomes.

View Figures

View References

1	World Cancer Report. International Agency for Research on Cancer. 2008, Available at. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.phpApril 29–2016
2	Dittmer J and Rody A: Cancer stem cells in breast cancer. Histol Histopathol. 28:827–838. 2013.PubMed/NCBI
3	Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS and Rameshwar P: Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 3:e25632008. View Article : Google Scholar : PubMed/NCBI
4	Terunuma H, Deng X, Dewan Z, Fujimoto S and Yamamoto N: Potential role of NK cells in the induction of immune responses: Implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI
5	Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, et al: Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 5:e115902010. View Article : Google Scholar : PubMed/NCBI
6	Yin T, Wang G, He S, Liu Q, Sun J and Wang Y: Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol. 300:41–45. 2016. View Article : Google Scholar : PubMed/NCBI
7	Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T and Matsumoto Y: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial. Clin Cancer Res. 8:1767–1771. 2002.PubMed/NCBI
9	Egawa K: Immuno-cell therapy of cancer in Japan. Anticancer Res. 24:3321–3326. 2004.PubMed/NCBI
10	Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N and Toi M: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
11	Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, et al: Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: Follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother. 62:1053–1060. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonikolis J and Georgoulias V: Docetaxel-induced lymphopenia in patients with solid tumors: A prospective phenotypic analysis. Cancer. 89:1380–1386. 2000. View Article : Google Scholar : PubMed/NCBI
13	Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11:359–377. 1957. View Article : Google Scholar : PubMed/NCBI
14	Sobin LH, Gospodarowicz MK and Wittekind CH: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; Oxford: 2009
15	Premkumar S, Dedeepiya VD, Terunuma H, Senthilkumar R, Srinivasan T, Reena HC, Preethy S and Abraham SJ: Cell based autologous immune enhancement therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix. Case Rep Oncol Med. 2013:9030942013.PubMed/NCBI
16	Manjunath SR, Ramanan G, Dedeepiya VD, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S and Abraham SJ: Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: A case report. Case Rep Oncol. 5:114–118. 2012. View Article : Google Scholar : PubMed/NCBI
17	Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, Murugan P, Thamaraikannan P, Srinivasan T, Preethy S and Abraham SJ: A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncol Lett. 3:435–440. 2012.PubMed/NCBI
18	Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK and Sharma DN: Inflammatory breast cancer: A single centre analysis. Asian Pac J Cancer Prev. 15:3207–3210. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M and Umansky V: Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol. 133:1610–1619. 2013. View Article : Google Scholar : PubMed/NCBI
20	Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 87:21–27. 2002. View Article : Google Scholar : PubMed/NCBI
21	Tai LH, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, et al: Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 73:97–107. 2013. View Article : Google Scholar : PubMed/NCBI
22	Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC and Sautès-Fridman C: The immune microenvironment: A major player I human cancers. Int Arch Allergy Immunol. 164:13–26. 2014. View Article : Google Scholar : PubMed/NCBI
23	Sznurkowski JJ, Zawrocki A and Biernat W: Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother. 63:297–303. 2014. View Article : Google Scholar : PubMed/NCBI
24	Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R and Al-Saleem T: Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 37:1213–1235. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hanna N and Fidler IJ: Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst. 65:801–809. 1980. View Article : Google Scholar : PubMed/NCBI